Wells Fargo
EFTR

Wells Fargo’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Wells Fargo’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19
Closed -$273 – 7652
2024
Q1 		$273 Buy
19
+6
+46% +$72 ﹤0.01% 6425
2023
Q4 		$147 Buy
13
+1
+8% +$13 ﹤0.01% 6676
2023
Q3 		$178 Buy
12
+9
+300% +$156 ﹤0.01% 6617
2023
Q2 		$66 Hold
3
– – ﹤0.01% 6982
2023
Q1 		$26 Hold
3
– – ﹤0.01% 7306
2022
Q4 		$32 Hold
3
– – ﹤0.01% 7148
2022
Q3 		$0 Hold
3
– – ﹤0.01% 7606
2022
Q2 		$0 Buy
3
+1
+50% +$60 ﹤0.01% 7717
2022
Q1 		$0 Hold
2
– – ﹤0.01% 8050
2021
Q4 		$0 Buy
+2
New +$464 ﹤0.01% 7998

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Wells Fargo's EFTR Position: Q2 2024 in Review

Wells Fargo sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2024, closing a stake of 19 shares — an estimated $273 sold.

Wells Fargo first reported a position in EFTR in Q4 2021 and held it in 10 quarters. The position peaked at $273 in Q1 2024. 18 funds tracked by Wall St. Rank hold EFTR as of Q2 2024.

  • Wells Fargo reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 19 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $273.
  • Wells Fargo first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
  • Wells Fargo's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $273 in Q1 2024.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.